Liraglutide treatment ameliorated these pathological changes, consistent with previous studies on experimental animals fed HFD.32, 33 The beneficial effects of GLP‐1 receptor agonists on NAFLD in humans have also been demonstrated in several studies.34, 35 The decrease in liver weight in liraglutide‐treated animals may be caused by the amelioration of fatty liver. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.